Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Alembic Pharmaceuticals Ltd. indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this time. This rating reflects a balance between the company’s strengths and challenges, signalling that the stock may offer moderate returns but with some risks or uncertainties that temper enthusiasm. The rating was revised from 'Sell' to 'Hold' on 13 August 2026, reflecting an improvement in the company’s overall profile, as evidenced by a 10-point increase in the Mojo Score from 48 to 58.
Here’s How Alembic Pharmaceuticals Looks Today
As of 16 September 2026, Alembic Pharmaceuticals presents a mixed but cautiously optimistic picture. The company’s Mojo Score of 58 places it in the 'Hold' category, reflecting average quality, attractive valuation, flat financial trends, and mildly bullish technical indicators. These factors combine to justify the current rating and provide a comprehensive view of the stock’s investment potential.
Quality Assessment
The quality grade for Alembic Pharmaceuticals is assessed as average. This suggests that while the company maintains a stable operational foundation, it does not exhibit exceptional strengths in areas such as profitability growth or operational efficiency. Notably, the company’s operating profit has declined at an annualised rate of -6.71% over the past five years, indicating challenges in sustaining long-term growth. However, the company demonstrates a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.28 times, which is a positive sign of financial stability and risk management.
Valuation Perspective
Valuation is one of the more favourable aspects of Alembic Pharmaceuticals’ current profile. The stock is considered attractively valued, trading at a discount relative to its peers’ historical averages. This is supported by a Return on Capital Employed (ROCE) of 11.6%, which, while modest, is sufficient to underpin the company’s valuation metrics. The Enterprise Value to Capital Employed ratio stands at 2.5, reinforcing the notion that the stock is reasonably priced. Additionally, the company’s Price/Earnings to Growth (PEG) ratio is 0.8, suggesting that the stock’s price is low relative to its earnings growth potential, which may appeal to value-oriented investors.
Financial Trend Analysis
Financially, Alembic Pharmaceuticals is experiencing a flat trend. The latest quarterly results for June 2026 showed stable but unspectacular performance, with interest expenses reaching a quarterly high of ₹27.61 crores. Despite this, the company’s profits have risen by 27.1% over the past year, a positive sign that contrasts with the stock’s negative return of -15.59% during the same period. This divergence suggests that the market may be undervaluing the company’s earnings growth, possibly due to concerns about its longer-term growth trajectory or sector-specific headwinds.
Technical Outlook
From a technical standpoint, the stock exhibits mildly bullish characteristics. Recent price movements show a 3-month gain of 9.99% and a 6-month gain of 21.98%, indicating some positive momentum. However, the stock has underperformed the broader market over the past year, with a 1-year return of -15.25% compared to the BSE500’s -4.75%. This underperformance may reflect investor caution or sector-specific challenges, but the technical indicators suggest potential for recovery or consolidation in the near term.
Investment Implications
For investors, the 'Hold' rating on Alembic Pharmaceuticals suggests a measured approach. The stock’s attractive valuation and improving profit metrics offer some upside potential, but the flat financial trend and average quality grade caution against aggressive accumulation. Investors may consider holding existing positions while monitoring upcoming quarterly results and sector developments for clearer signs of sustained growth or risk mitigation.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Sector and Market Context
Alembic Pharmaceuticals operates within the Pharmaceuticals & Biotechnology sector, a space characterised by regulatory complexities and competitive pressures. The company’s smallcap status means it is more susceptible to market volatility and sector-specific risks compared to larger peers. Despite these challenges, the sector’s long-term growth prospects remain intact, driven by increasing healthcare demand and innovation. Alembic’s current valuation discount may reflect these sector risks, but also presents an opportunity for investors willing to accept moderate risk in exchange for potential gains.
Summary of Key Metrics as of 16 September 2026
To summarise, the stock’s recent performance metrics are as follows: a 1-day change of -0.27%, a 1-week gain of 0.47%, a 1-month decline of 1.15%, a 3-month gain of 9.99%, and a 6-month gain of 21.98%. Year-to-date, the stock is down by 3.13%, and over the past year, it has declined by 15.25%. These figures highlight a mixed performance with some recovery in recent months but overall underperformance relative to the broader market.
Conclusion
In conclusion, Alembic Pharmaceuticals Ltd.’s 'Hold' rating by MarketsMOJO reflects a balanced view of the company’s current fundamentals, valuation, financial trends, and technical outlook. While the stock is attractively valued and shows signs of profit growth, challenges in long-term operating profit trends and recent underperformance temper enthusiasm. Investors should consider this rating as a signal to maintain positions with caution, keeping a close eye on future earnings and sector developments to reassess the stock’s potential.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
